Axsome Therapeutics, Inc. (AXSM) stock
AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$134.00−1.95 (-1.43%)
Close on Nov 18, 2026Market cap $7.02BP/E –Yield –
Axsome Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Axsome Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $776.57M, up 56.9% year over year. For fiscal 2025 it was $638.50M, up 65.5% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $638.50M | +65.5% |
| FY2024 | Dec 31, 2024 | $385.69M | +42.5% |
| FY2023 | Dec 31, 2023 | $270.60M | +440.8% |
| FY2022 | Dec 31, 2022 | $50.04M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $218.38M | +45.5% |
| Q1 FY2026 | Mar 31, 2026 | $191.20M | +57.4% |
| Q4 FY2025 | Dec 31, 2025 | $196.00M | +65.0% |
| Q3 FY2025 | Sep 30, 2025 | $170.99M | +63.2% |
| Q2 FY2025 | Jun 30, 2025 | $150.04M | +72.1% |
| Q1 FY2025 | Mar 31, 2025 | $121.46M | +62.0% |
| Q4 FY2024 | Dec 31, 2024 | $118.77M | +66.0% |
| Q3 FY2024 | Sep 30, 2024 | $104.76M | +81.3% |
| Q2 FY2024 | Jun 30, 2024 | $87.17M | +86.7% |
| Q1 FY2024 | Mar 31, 2024 | $75.00M | -20.7% |
| Q4 FY2023 | Dec 31, 2023 | $71.53M | +193.5% |
| Q3 FY2023 | Sep 30, 2023 | $57.79M | +243.1% |
| Q2 FY2023 | Jun 30, 2023 | $46.70M | +429.5% |
| Q1 FY2023 | Mar 31, 2023 | $94.58M | – |
| Q4 FY2022 | Dec 31, 2022 | $24.37M | – |
| Q3 FY2022 | Sep 30, 2022 | $16.85M | – |
| Q2 FY2022 | Jun 30, 2022 | $8.82M | – |
| Q3 FY2021 | Sep 30, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $0 | – |
See a number that looks wrong?